Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.71)
# 3,978
Out of 4,981 analysts
55
Total ratings
32.65%
Success rate
-26.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $6.61 | +66.41% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $18.79 | +64.98% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $0.95 | +1,890.36% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $5.83 | +260.21% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $3.57 | +40.06% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.52 | +952.63% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.62 | +7,307.41% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $6.36 | +293.08% | 2 | May 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $6.02 | +33,122.59% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.23 | +469.11% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.00 | +400.00% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $13.01 | +361.18% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $2.17 | +176.50% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.88 | +104.92% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.60 | +40,033.78% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $10.26 | +1,674.74% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.19 | +42,094.09% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.02 | +562.25% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.40 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.66 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.37 | +153.16% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.17 | +240.63% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $7.50 | +139,900.00% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.48 | +1,391.94% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $48.68 | +516.27% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $560.00 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $83.10 | +7.10% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $141.90 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $15,000 | $5.29 | +283,453.88% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.38 | +14,017.65% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.18 | +330.62% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $6.61
Upside: +66.41%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $18.79
Upside: +64.98%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $0.95
Upside: +1,890.36%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $5.83
Upside: +260.21%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $3.57
Upside: +40.06%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.52
Upside: +952.63%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.62
Upside: +7,307.41%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $6.36
Upside: +293.08%
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $6.02
Upside: +33,122.59%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.23
Upside: +469.11%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $2.00
Upside: +400.00%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $13.01
Upside: +361.18%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $2.17
Upside: +176.50%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.88
Upside: +104.92%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.60
Upside: +40,033.78%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $10.26
Upside: +1,674.74%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.19
Upside: +42,094.09%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $3.02
Upside: +562.25%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.40
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.66
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.37
Upside: +153.16%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.17
Upside: +240.63%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $7.50
Upside: +139,900.00%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.48
Upside: +1,391.94%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $48.68
Upside: +516.27%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $560.00
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $83.10
Upside: +7.10%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $141.90
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $15,000
Current: $5.29
Upside: +283,453.88%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.38
Upside: +14,017.65%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.18
Upside: +330.62%